- Home
- FKWL vs OTLK Comparison
FKWL vs OTLK Comparison
Compare FKWL & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FKWL
- OTLK
- Stock Information
- Founded
- FKWL 1981
- OTLK 2010
- Country
- FKWL United States
- OTLK United States
- Employees
- FKWL N/A
- OTLK N/A
- Industry
- FKWL Telecommunications Equipment
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FKWL Utilities
- OTLK Health Care
- Exchange
- FKWL Nasdaq
- OTLK Nasdaq
- Market Cap
- FKWL 46.5M
- OTLK 48.3M
- IPO Year
- FKWL 1996
- OTLK 2016
- Fundamental
- Price
- FKWL $3.98
- OTLK $2.04
- Analyst Decision
- FKWL
- OTLK Strong Buy
- Analyst Count
- FKWL 0
- OTLK 5
- Target Price
- FKWL N/A
- OTLK $9.60
- AVG Volume (30 Days)
- FKWL 11.6K
- OTLK 988.5K
- Earning Date
- FKWL 05-15-2025
- OTLK 08-13-2025
- Dividend Yield
- FKWL N/A
- OTLK N/A
- EPS Growth
- FKWL N/A
- OTLK N/A
- EPS
- FKWL N/A
- OTLK 0.83
- Revenue
- FKWL $45,276,495.00
- OTLK N/A
- Revenue This Year
- FKWL N/A
- OTLK N/A
- Revenue Next Year
- FKWL N/A
- OTLK $419.06
- P/E Ratio
- FKWL N/A
- OTLK $2.46
- Revenue Growth
- FKWL 8.62
- OTLK N/A
- 52 Week Low
- FKWL $3.67
- OTLK $0.87
- 52 Week High
- FKWL $7.45
- OTLK $8.70
- Technical
- Relative Strength Index (RSI)
- FKWL 44.28
- OTLK 53.28
- Support Level
- FKWL $3.91
- OTLK $2.02
- Resistance Level
- FKWL $4.04
- OTLK $2.12
- Average True Range (ATR)
- FKWL 0.07
- OTLK 0.16
- MACD
- FKWL 0.01
- OTLK -0.02
- Stochastic Oscillator
- FKWL 25.93
- OTLK 32.79
About FKWL Franklin Wireless Corp.
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.